Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort.

Frank Trudo¹, Lee Kallenbach², Joseph Vasey², Yen Chung¹, Alan Wilk², Lukas Slipski², Dan O'Brien², Charlie Strange³

¹Respiratory and Inflammation Therapeutic Area, AstraZeneca, Wilmington, DE, USA.

²Life Sciences, Practice Fusion, San Francisco, CA, USA.

³Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.

PubMed PMC DOI PDF

Abstract

PURPOSE: We sought to describe clinical and economic outcomes for COPD patients by blood eosinophil (EOS) count. METHODS: This retrospective cohort study of COPD patients used data from the Practice Fusion electronic medical records (EMR) database linked to Symphony Health Solutions transactional pharmacy, medical, outpatient, and inpatient claims data to evaluate COPD-related and all-cause healt…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.